RIGL

Rigel Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-03

Figures on this page computed 2026-11-08 12:40 UTC

Last close

51.29USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-03

1.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
The filing itself
n/mNet marginnet income exceeds revenue
Net income exceeds revenue.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.68x

-116.91x

n/a

1.16x

2.04x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-03

Sales2.68x
Its own average over 10 years, 109.7M.
Profit-116.91x
Its own average over 10 years, -3.1M.
Free cash flown/a
Its own average over 7 years, -54.2M.
Debt1.16x
Its own average over 7 years, 46.2M.
Price2.04x
Its own average over 11 years, 25. Market data, 2026-11-04

Profit is furthest from its own average, at -116.91 times.

Sales is 2.68 times its own 10-year average; Profit is -116.91 times its own 10-year average; Debt is 1.16 times its own 7-year average; Price is 2.04 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-03

Sales against its own 10-year average2.68
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
Profit against its own 10-year average-116.91
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
Free cash flow against its own 7-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
Debt against its own 7-year average1.16
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
Price against its own 11-year average2.04Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD